London Daily

Focus on the big picture.
Saturday, Jul 12, 2025

US won't rely on UK for Covid vaccine safety tests, says Nancy Pelosi

US won't rely on UK for Covid vaccine safety tests, says Nancy Pelosi

House speaker says UK system is not on a par with US’s ‘very stringent rules’ about vaccines
The speaker of the House of Representatives, Nancy Pelosi, has taken aim at the British vaccine testing safety regime, warning that UK approval of a vaccine would not automatically mean it was safe according to the US’s own procedures.

Amid a race to produce an effective vaccine against Covid-19 that meets broad international acceptance for safety, Pelosi’s comments appear partly motivated by concern that any quick and unilateral British approval of a vaccine might be embraced by Donald Trump for political gain, perhaps even before the 3 November election.

At present, one of the leading global candidates is the AstraZeneca/Oxford University-developed vaccine now undergoing phase III trials, which were briefly halted to examine whether an illness in a participant was related to the vaccine.

The trial remains paused in the US despite restarting in other places it was being conducted.

“We have very stringent rules about the Food and Drug Administration here about clinical trials, timing, number of people etc, so that when a drug is approved by the FDA that it’s safe and efficacious, then it has the trust of the American people,” Pelosi remarked.

“My concern is that the UK’s system for that kind of judgment is not on par with ours. So if Boris Johnson decides he’s going to approve a drug and this president embraces that, that’s the concern I have.”

Pelosi’s intervention raises questions for a number of reasons, not least the widespread assumption that there is little likelihood of the AstraZeneca vaccine being approved, under any circumstances, before the end of the year.

Trump suggested in August he might seek an emergency US authorisation for a British vaccine, but there is no evidence that the British vaccine is close to being approved.

Trump’s insistence that a vaccine will be approved “momentarily” has drawn criticism from scientists, who believe the president could undermine public trust. His repeated comments led nine pharmaceutical companies to issue a joint statement pledging to follow the science, not political pressure, while developing a vaccine.

The UK government has consulted on changing the legislation so that the Medicines and Healthcare products Regulatory Agency can approve a vaccine before December – if the trial data is ready at that time and satisfactory – but any MHRA approval is likely to be in line with the same stringent approach as other European agencies.

Even then, the US FDA would still have to look at the vaccine itself.
Newsletter

Related Articles

0:00
0:00
Close
Reparations argument crushed
Rainmaker CEO Says Cloud Seeding Paused Before Deadly Texas Floods
A 92-year-old woman, who felt she doesn't belong in a nursing home, escaped the death-camp by climbing a gate nearly 8 ft tall
French Journalist Acquitted in Controversial Case Involving Brigitte Macron
Elon Musk’s xAI Targets $200 Billion Valuation in New Fundraising Round
Kraft Heinz Considers Splitting Off Grocery Division Amid Strategic Review
Trump Proposes Supplying Arms to Ukraine Through NATO Allies
EU Proposes New Tax on Large Companies to Boost Budget
Trump Imposes 35% Tariffs on Canadian Imports Amid Trade Tensions
Junior Doctors in the UK Prepare for Five-Day Strike Over Pay Disputes
US Opens First Rare Earth Mine in Over 70 Years in Wyoming
Kurdistan Workers Party Takes Symbolic Step Towards Peace in Northern Iraq
Bitcoin Reaches New Milestone of $116,000
Biden’s Doctor Pleads the Fifth to Avoid Self-Incrimination on President’s Medical Fitness
Grok Chatbot Faces International Backlash for Antisemitic Content
Severe Heatwave Claims 2,300 Lives Across Europe
NVIDIA Achieves Historic Milestone as First Company Valued at $4 Trillion
Declining Beer Consumption Signals Cultural Shift in Germany
Linda Yaccarino Steps Down as CEO of X After Two Years
US Imposes New Tariffs on Brazilian Exports Amid Political Tensions
Azerbaijan and Armenia are on the brink of a historic peace deal.
Emails Leaked: How Passenger Luggage Became a Side Income for Airport Workers
Polish MEP: “Dear Leftists - China is laughing at you, Russia is laughing, India is laughing”
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Weinstein Victim’s Lawyer Says MeToo Movement Still Strong
U.S. Enacts Sweeping Tax and Spending Legislation Amid Trade Policy Shifts
Football Mourns as Diogo Jota and Brother André Silva Laid to Rest in Portugal
Labour Expected to Withdraw Support for Special Needs Funding Model
Leaked Audio Reveals Tory Aide Defending DEI Record
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
London Stock Exchange Faces Historic Low in Initial Public Offerings
A new online platform has emerged in the United Kingdom, specifically targeting Muslim men seeking virgin brides
Trump Celebrates Independence Day with B-2 Flyover and Signs Controversial Legislation
Boris Johnson Urges Conservatives to Ignore Farage
SNP Ordered to Update Single-Sex Space Guidance Within Days
Starmer Set to Reject Calls for Wealth Taxes
Stolen Century-Old Rolls-Royce Recovered After Hotel Theft
Macron Presses Starmer to Recognise Palestinian State
Labour Delayed Palestine Action Ban Over Riot Concerns
Swinney’s Tax Comments ‘Offensive to Scots’, Say Tories
High Street Retailers to Enforce Bans on Serial Shoplifters
Music Banned by Henry VIII to Be Performed After 500 Years
Steve Coogan Says Working Class Is Being ‘Ethnically Cleansed’
Home Office Admits Uncertainty Over Visa Overstayer Numbers
JD Vance Questions Mandelson Over Reform Party’s Rising Popularity
Macron to Receive Windsor Carriage Ride in Royal Gesture
Labour Accused of ‘Hammering’ Scots During First Year in Power
BBC Head of Music Stood Down Amid Bob Vylan Controversy
Corbyn Eyes Hard-Left Challenge to Starmer’s Leadership
London Tube Trains Suspended After Major Fire Erupts Nearby
×